Good news on the cardiovascular front vs Eli Lilly.

Q2 outlook is weak but current levels offer an attractive entry point.

Slight beat in Operating level for FY results. Cautious guidance is in line with consensus.

Solid H1 results - FY guidance marginally upgrade.

A bet on the next data center wave thanks to unique technology.

Acquisition in South Korea is a positive.